MAHIDOL UNIVERSITY

Dr. George Tsai founded AMS BioteQ in 2018, focusing on drug development and innovative medical materials research, leveraging Taiwan’s unique natural resources to combat infectious diseases and expand into the global anti-infection market. The company successfully isolated compounds YUAN-01 and YUAN-03 from Antrodia camphorata, showing excellent antibacterial properties, and later identified potential antiviral effects against COVID-19. AMS BioteQ also targets Dengue, Zika, and Avian Influenza viruses, with compounds like AMS-2140 showing strong antiviral effects in animal experiments. The company employs early licensing strategies to secure funding and collaborates with international partners for clinical trials. Additionally, AMS BioteQ develops innovative medical devices like the SIPSIP Foam Dressing for wound care, targeting the Japanese market, and plans to launch multiple dressing products by 2026.

Professor Pornsak Sriamornsak, a Charles Sturt University PhD graduate, has been awarded a Charles Sturt Alumni Award for excellence in research and significant contributions to the pharmaceutical industry. His innovations in drug delivery systems, pharmaceutical nanotechnology, and 3D printing have advanced pharmaceutical knowledge and practices worldwide.